<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02166047</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-283-1059</org_study_id>
    <secondary_id>2014-001400-22</secondary_id>
    <nct_id>NCT02166047</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of GS-9620 for the Treatment of Chronic Hepatitis B Virus in Virally-Suppressed Subjects</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety and Efficacy of GS-9620 for the Treatment of Virally-Suppressed Subjects With Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability, and efficacy of GS-9620 in virologically
      suppressed adults with chronic hepatitis B virus (HBV) infection who are currently being
      treated with oral antivirals (OAV). Participants will be randomized in 3 sequential cohorts.
      Within each cohort, participants will be randomized in a 1:3:3:3 ratio to placebo or one of
      the doses of GS-9620 (1, 2, or 4 mg) and all participants will continue on their current oral
      antiviral treatment for the entire duration of the study. Cohorts A, B, and C will consist of
      a different treatment period of 4, 8, or 12 weeks, respectively, and will be followed to Week
      48. After Cohort A completes treatment, a safety review will be conducted by an external data
      monitoring committee prior to beginning Cohort B. Another safety review will be conducted
      after Cohort B completes treatment prior to beginning Cohort C.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in log10 IU/ml serum hepatitis B surface antigen (HBsAg) from baseline to Week 24</measure>
    <time_frame>Up to Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with hepatitis B e antigen (HBeAg) loss and seroconversion at Weeks 24 and 48</measure>
    <time_frame>Up to Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with HBsAg loss and seroconversion at Weeks 24 and 48</measure>
    <time_frame>Up to Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in serum HBsAg from baseline to Weeks 4, 8, 12 and 48 (measured in log10 IU/mL)</measure>
    <time_frame>Up to Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with virological breakthrough</measure>
    <time_frame>Up to Week 12</time_frame>
    <description>Virological breakthrough is defined as having HBV DNA &gt; 69 IU/ml with confirmation &gt; 2 weeks after the initial test in the setting of satisfactory adherence to treatment with oral antivirals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with drug resistance mutations at Week 48</measure>
    <time_frame>Up to Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with ≥ 1 log10 decline in serum HBsAg titers from baseline at Weeks 4,8,12, 24 and 48</measure>
    <time_frame>Up to Week 48</time_frame>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">162</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Placebo 4 Weeks (Cohort A)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo to match GS-9620 once a week for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GS-9620 1 mg 4 Weeks (Cohort A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive GS-9620 1 mg once a week for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GS-9620 2 mg 4 Weeks (Cohort A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive GS-9620 2 mg once a week for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GS-9620 4 mg 4 Weeks (Cohort A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive GS-9620 4 mg once a week for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 8 Weeks (Cohort B)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo to match GS-9620 once a week for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GS-9620 1 mg 8 Weeks (Cohort B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive GS-9620 1 mg once a week for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GS-9620 2 mg 8 Weeks (Cohort B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive GS-9620 2 mg once a week for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GS-9620 4 mg 8 Weeks (Cohort B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive GS-9620 4 mg once a week for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 12 Weeks (Cohort C)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo to match GS-9620 once a week for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GS-9620 1 mg 12 Weeks (Cohort C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive GS-9620 1 mg once a week for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GS-9620 2 mg 12 Weeks (Cohort C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive GS-9620 2 mg once a week for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GS-9620 4 mg 12 Weeks (Cohort C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive GS-9620 4 mg once a week for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-9620</intervention_name>
    <description>GS-9620 tablets administered orally every 7 days</description>
    <arm_group_label>GS-9620 1 mg 4 Weeks (Cohort A)</arm_group_label>
    <arm_group_label>GS-9620 2 mg 4 Weeks (Cohort A)</arm_group_label>
    <arm_group_label>GS-9620 4 mg 4 Weeks (Cohort A)</arm_group_label>
    <arm_group_label>GS-9620 1 mg 8 Weeks (Cohort B)</arm_group_label>
    <arm_group_label>GS-9620 2 mg 8 Weeks (Cohort B)</arm_group_label>
    <arm_group_label>GS-9620 4 mg 8 Weeks (Cohort B)</arm_group_label>
    <arm_group_label>GS-9620 1 mg 12 Weeks (Cohort C)</arm_group_label>
    <arm_group_label>GS-9620 2 mg 12 Weeks (Cohort C)</arm_group_label>
    <arm_group_label>GS-9620 4 mg 12 Weeks (Cohort C)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to match GS-9620</intervention_name>
    <description>Placebo to match GS-9620 tablets administered orally every 7 days</description>
    <arm_group_label>Placebo 4 Weeks (Cohort A)</arm_group_label>
    <arm_group_label>Placebo 8 Weeks (Cohort B)</arm_group_label>
    <arm_group_label>Placebo 12 Weeks (Cohort C)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have the ability to understand and sign a written informed consent form; consent
             must be obtained prior to initiation of study procedures

          -  Documented evidence of chronic HBV infection (e.g. HBsAg positive for more than 6
             months) with detectable HBsAg levels at screening

          -  Have been on approved HBV OAV treatment for ≥ 1 year prior to screening, with HBV DNA
             below lower limit of quantitation (LLOQ), measured at least once, 6 or more months
             prior to screening, and HBV DNA &lt; 20 IU/ml at screening

          -  Currently taking an approved HBV OAV (tenofovir, entecavir, adefovir, lamivudine or
             telbivudine, either as single agents or in combination) with no change in regimen for
             3 months prior to screening

          -  Willing to provide blood sample for toll-like receptor 7 (TLR-7) and interleukin 28 B
             (IL28B) single-nucleotide polymorphism (SNP) assessment

          -  Must be willing and able to comply with all study requirements

        Exclusion Criteria:

          -  Extensive bridging fibrosis or cirrhosis

          -  Lab parameters not within defined thresholds for neutropenia, anemia,
             thrombocytopenia, leukopenia, or other evidence of inadequate liver function

          -  Co-infection with hepatitis C virus (HCV), HIV, or hepatitis D virus (HDV)

          -  Evidence of hepatocellular carcinoma

          -  Malignancy within 5 years prior to screening, with the exception of specific cancers
             that are cured by surgical resection (basal cell skin cancer, etc). Participants under
             evaluation for possible malignancy are not eligible

          -  Significant cardiovascular, pulmonary, or neurological disease

          -  Any of the following conditions that may worsen in response to interferon (IFN):

               -  Autoimmune disease (e.g. lupus erythematosus, rheumatoid arthritis, inflammatory
                  bowel disease, sarcoidosis, moderate or severe psoriasis)

               -  Poorly controlled diabetes mellitus

               -  Significant psychiatric disorders

               -  Thyroid disorder (unless controlled under treatment)

               -  Significant pulmonary diseases (e.g. chronic obstructive pulmonary disease)

               -  Retinal disease

               -  Immunodeficiency disorders

          -  Received solid organ or bone marrow transplant

          -  Received prolonged therapy with immunomodulators (e.g. corticosteroids) or biologics
             (e.g. monoclonal Ab, interferon) within 3 months of screening

          -  Use of another investigational agents within 3 months of screening

          -  Current alcohol or substance abuse judged by the investigator to potentially interfere
             with compliance

          -  Females who are pregnant or may wish to become pregnant during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92154</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96734</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Flushing</city>
        <state>New York</state>
        <zip>11355</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 3P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Giovanni Rotondo</city>
        <state>FG</state>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milan</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Parma</city>
        <zip>43126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Auckland</city>
        <zip>1142</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2014</study_first_submitted>
  <study_first_submitted_qc>June 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2014</study_first_posted>
  <disposition_first_submitted>December 16, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>December 16, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 19, 2016</disposition_first_posted>
  <last_update_submitted>December 16, 2016</last_update_submitted>
  <last_update_submitted_qc>December 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis B</keyword>
  <keyword>HBV</keyword>
  <keyword>GS-9620</keyword>
  <keyword>TLR-7 Agonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

